Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting Information [Line Items]
Total research and development	$ 5,118	$ 1,442	$ 9,192	$ 2,426
Total general and administrative	4,132	1,466	7,929	2,241
Loss from operations	(9,250)	(2,908)	(17,121)	(4,667)
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	1,235	422	2,389	425
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	(212)		(339)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	354		700
QTORIN Rapamycin CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	1,517	40	2,289	153
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	1,501	704	2,823	1,351
Total general and administrative	1,744	411	3,197	757
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	385	183	632	351
Total general and administrative	914	786	1,910	946
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	338	93	698	146
Total general and administrative	$ 1,474	$ 269	$ 2,822	$ 538